- G Ireland1,2, R Simmons1,2, M Hickman3,4, M Ramsay1, C Sabin2,5, S Mandal1,2
-
View Affiliations Hide AffiliationsAffiliations: 1 National Infection Service, Public Health England, London, United Kingdom 2 The National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London, United Kingdom 3 The National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at University of Bristol, Bristol, United Kingdom 4 Population Health Sciences, Bristol Medical School, Bristol, United Kingdom 5 University College London, London, United KingdomGeorgina IrelandGeorgina.ireland phe.gov.uk
-
View Citation Hide Citation
Citation style for this article: Ireland G, Simmons R, Hickman M, Ramsay M, Sabin C, Mandal S. Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017. Euro Surveill. 2019;24(41):pii=1900176. https://doi.org/10.2807/1560-7917.ES.2019.24.41.1900176 Received: 08 Mar 2019; Accepted: 02 Aug 2019
Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017
Abstract
Liver transplantation is an important measure of burden from hepatitis C virus (HCV)-associated liver disease.
To describe transplant rates and survival in individuals with HCV infection from 2008 to 2017 in England through data linkage.
This is a retrospective observational cohort study. Laboratory reports of HCV infection were linked to the Liver Transplant Registry for individuals aged 15 years and over, first diagnosed between 1998 and 2017. We estimated age-sex standardised incidence rates and used Poisson regression to investigate predictors of liver transplantation and test for a change in incidence after introduction of direct-acting antivirals (DAAs) in 2014. Kaplan-Meier survival analysis was used to calculate post-transplant survival rates.
Of 124,238 individuals diagnosed with HCV infection, 1,480 were registered and 1,217 received a liver transplant. Of individuals registered, 1,395 had post-HCV cirrhosis and 636 had hepatocellular carcinoma (618 also had post-HCV cirrhosis). Median time from HCV diagnosis to transplant was 3.4 years (interquartile range: 1.3–6.8 years). Liver transplant rates were lower 2014–17 compared with 2011–13 (incidence rate ratio: 0.64; 95% confidence interval: 0.55–0.76). Survival rates were 93.4%, 79.9% and 67.9% at 1, 5 and 10 years, respectively. Data linkage showed minimal under-reporting of HCV in the transplant registry.
In the post-DAA era, liver transplant rates have fallen in individuals with HCV infection, showing early impact of HCV treatment scale-up; but the short time from HCV diagnosis to liver transplant suggests late diagnosis is a problem.

Article metrics loading...

-
From This Site
/content/10.2807/1560-7917.ES.2019.24.41.1900176dcterms_title,dcterms_subject,pub_keyword105 -
PubMed
-
Google Scholar

Full text loading...
References
-
Harris RJ, Harris HE, Mandal S, Ramsay M, Vickerman P, Hickman M, et al. Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data. J Viral Hepat. 2019;26(5):541-51. https://doi.org/10.1111/jvh.13063 PMID: 30663179
-
Public Health England (PHE). Hepatitis C in England- 2019 report. Working to eliminate hepatitis C as a major public health threat. London: PHE; 2019. Available from
-
Harris RJ, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol. 2014;61(3):530-7. https://doi.org/10.1016/j.jhep.2014.05.008 PMID: 24824282
-
Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43(6):674-96. https://doi.org/10.1111/apt.13514 PMID: 26787287
-
Public Health England (PHE). Hepatitis C treatment monitoring in England. Content, completeness and preliminary findings from the Hepatitis C patient registry and treatment outcome system. London: PHE; 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/756748/HCV_treatment_monitoring_report_2018.pdf
-
Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, et al. HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224-31. https://doi.org/10.1016/j.jhep.2016.01.029 PMID: 26829205
-
Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017;9(7):352-67. https://doi.org/10.4254/wjh.v9.i7.352 PMID: 28321272
-
Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, et al. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral Hepat. 2019;26(2):231-5. https://doi.org/10.1111/jvh.13022 PMID: 30339294
-
Young K, Liu B, Bhuket T, Gish RG, Wong RJ. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. J Viral Hepat. 2019;26(3):350-61. https://doi.org/10.1111/jvh.13039 PMID: 30412318
-
Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, Zanetto A, et al. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World J Gastroenterol. 2018;24(38):4403-11. https://doi.org/10.3748/wjg.v24.i38.4403 PMID: 30344424
-
Dirchwolf M, Marciano S, Giunta DH, Posadas-Martínez ML, Biggins SW, Ruf AE. Trends in liver transplantation for hepatitis C in a country with reduced access to direct-acting antiviral agents. Clin Transplant. 2018;32(4):e13230. https://doi.org/10.1111/ctr.13230 PMID: 29485711
-
Simmons R, Ireland G, Ijaz S, Ramsay M, Mandal SNational Institute for Health Research Health Protection Research Unit. (NIHR HPRU) in Blood Borne, Sexually Transmitted Infections. Causes of death among persons diagnosed with hepatitis C infection in the pre- and post-DAA era in England: A record linkage study. J Viral Hepat. 2019;26(7):873-80. https://doi.org/10.1111/jvh.13096 PMID: 30896055
-
Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ahmad F, Boxall E, et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect. 2007;135(3):417-26. https://doi.org/10.1017/S0950268806006832 PMID: 16836798
-
Public Health England (PHE). Annual report from the sentinel surveillance study of blood borne virus testing in England: data for January to December 2017. London: PHE; 2018. Available from
-
Office for National Statistics (ONS). Population estimates 2018. Newport: ONS. [Accessed 15 Dec 2018]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates
-
Ireland G, Mandal S, Hickman M, Ramsay M, Harris R, Simmons R. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Euro Surveill. 2019;24(30):1800695. https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800695 PMID: 31362807
-
Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician. 2017;9(10):5646-56. https://doi.org/10.19082/5646 PMID: 29238510
-
Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016;22(35):8050-9. https://doi.org/10.3748/wjg.v22.i35.8050 PMID: 27672299
-
Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, et al. members of the Lazio Region HCV treatment group. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis. 2018;18(1):223. https://doi.org/10.1186/s12879-018-3125-6 PMID: 29769038
-
Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62(3):715-25. https://doi.org/10.1002/hep.27922 PMID: 26033798
-
van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485-93. https://doi.org/10.1016/j.jhep.2016.10.017 PMID: 27780714
-
Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017;12(10):e0185728. https://doi.org/10.1371/journal.pone.0185728 PMID: 28977040
-
Lau SY, Woodman RJ, Silva MF, Muller K, Libby J, Chen JW, et al. Good outcomes of liver transplantation for hepatitis C at a low volume centre. Ann Hepatol. 2016;15(2):207-14. PMID: 31196402
-
NHS Blood and Transplant. Annual report on liver transplantation- report for 2015/2016 (1 April 2006 – 31 March 2016). London: NHS; 2016. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/1314/organ_specific_report_liver_2016.pdf
-
Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al. Chronic Hepatitis Cohort Study. (CHeCS) Investigators. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58(8):1055-61. https://doi.org/10.1093/cid/ciu077 PMID: 24523214
-
McDonald SA, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Graham L, et al. The growing contribution of hepatitis C virus infection to liver-related mortality in Scotland. Euro Surveill. 2010;15(18):19562. PMID: 20460092
-
World Health Organisation (WHO). Global Health Sector Strategy on Viral Hepatitis 2016-2021- Towards ending viral hepatitis. 2016. Geneva: WHO; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=B414D1806598317BE385218FA7F29E6A?sequence=1

Data & Media loading...
